VRNA
FY2026 EPS Estimate
$1.19
FY2026E EPS$1.19
FY2027E EPS$3.97

Analyst Sentiment

Wall St. Consensus
Buy
14 analysts·Moderate coverage
66
Score
9 Buy (64%)5 Hold (36%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
964%
Hold
536%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$26.00
-75.7%
Consensus
$74.00
-30.8%
Bull
$170.00
+59.0%
12-Month Target Range14 analysts
$26.00$74.00$170.00
Current $106.91Consensus
Current Price
$106.91
Above Consensus
$32.91

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+61.25%
EPS+234.58%
FY2028
Rev+41.37%
EPS+2.70%
FY2029
Rev+25.22%
EPS+37.50%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$777M$1.25B$1.77B$2.22B
Low$596M$1.20B$1.35B$1.70B
High$936M$1.31B$2.09B$2.61B
EBITDA Avg$-155M$-251M$-354M$-444M
Low$-187M$-262M$-418M$-523M
High$-119M$-240M$-271M$-339M
EBIT Avg$-155M$-251M$-354M$-444M
Low$-187M$-262M$-418M$-523M
High$-119M$-240M$-271M$-339M
Net Income Avg$87M$304M$333M$457M
Low$35M$206M$231M$317M
High$138M$402M$410M$563M
EPS Avg$1.19$3.97$4.08$5.61
Low$0.43$2.52$2.83$3.89
High$1.70$4.93$5.03$6.91
Analysts (Rev / EPS)7 / 56 / 32 / 15 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$193M$227M
Low$193M$227M
High$193M$227M
EBITDA Avg$-39M$-45M
Low$-39M$-45M
High$-39M$-45M
EBIT Avg$-39M$-45M
Low$-39M$-45M
High$-39M$-45M
Net Income Avg$16M$22M
Low$16M$22M
High$16M$22M
EPS Avg$0.18$0.25
Low$0.18$0.25
High$0.18$0.25
Analysts (Rev / EPS)1 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Jul 14, 2025H.C. Wainwright
Verona Pharma downgraded to Neutral from Buy at H.C. Wainwright
Target:$107.00
+2.2%from $104.67
Jun 30, 2025Wolfe Research
Verona Pharma initiated with an Outperform at Wolfe Research
Target:$170.00
+79.7%from $94.58
Jun 23, 2025Piper Sandler
Verona Pharma price target raised to $160 from $76 at Piper Sandler
Target:$160.00
+64.9%from $97.05
Apr 21, 2025Cantor Fitzgerald
Cantor starts Verona at Overweight, says momentum 'just getting started'
Target:$80.00
+33.2%from $60.07
Feb 28, 2025Roth Capital
Verona Pharma price target raised to $83 from $68 at Roth MKM
Target:$83.00
+19.2%from $69.63
Feb 28, 2025H.C. Wainwright
Verona Pharma price target raised to $75 from $60 at H.C. Wainwright
Target:$75.00
+7.7%from $69.63
Jan 10, 2025Roth Capital
Verona Pharma initiated with a Buy at Roth MKM
Target:$68.00
+50.4%from $45.20
Jan 8, 2025Wells Fargo
Verona Pharma price target raised to $74 from $64 at Wells Fargo
Target:$74.00
+49.3%from $49.55
Nov 5, 2024H.C. Wainwright
Verona Pharma (VRNA) PT Raised to $42 at H.C. Wainwright
Target:$42.00
+9.4%from $38.39
Jul 22, 2024Canaccord Genuity
Verona Pharma (VRNA) PT Raised to $37 at Canaccord Genuity
Target:$37.00
+61.2%from $22.95
Jun 27, 2024H.C. Wainwright
Verona Pharma price target raised to $36 from $32 at H.C. Wainwright
Target:$36.00
+145.1%from $14.69
May 28, 2024Jefferies
Expert likely to prescribe more ensifentrine than dupixent, says Jefferies
Target:$38.00
+204.0%from $12.50
Apr 16, 2024Piper Sandler
Verona Pharma (VRNA) PT Raised to $36 at Piper Sandler
Target:$36.00
+127.8%from $15.80
Dec 21, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $32
Target:$32.00
+72.1%from $18.59
Dec 20, 2022Wedbush
Wedbush ups Verona Pharma target to $30 on 'impressive' COPD data
Target:$30.00
+66.2%from $18.05
Dec 20, 2022Truist Financial
Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $28
Target:$28.00
+54.5%from $18.13
Dec 20, 2022BTIG
BTIG Maintains Buy on Verona Pharma, Raises Price Target to $26
Target:$26.00
+43.3%from $18.14
Aug 30, 2022Canaccord Genuity
Verona Pharma (VRNA) Stock: $27 Target And Buy Rating
Target:$27.00
+163.4%from $10.25
Aug 30, 2022Wedbush
Verona Pharma (VRNA) Stock: $23 Target And Outperform Rating
Target:$23.00
+132.3%from $9.90
Aug 30, 2022H.C. Wainwright
Verona Pharma (VRNA) Stock: $30 Target And Overweight Rating
Target:$30.00
+203.0%from $9.90
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.